Fundraising FoxJeito Capital — Full Portfolio
26 tracked investments · listed companies and verified rows first
Advesya is a clinical-stage biotech company developing cancer and autoimmune disease therapies that target IL-1RAP, an antigen upregulated in various cancers and autoimmune conditions.
BiotechHealthtechMedical DevicesBesançon, FR
Christophe Ferrand(Academic Founder and Board Member)inMarina Deschamps(Academic Founder)inAndré Baruchel(Founder and Board Member)in
BoardKsenija Pavletic(A.I. Chief Executive Officer, Board Member)in
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.
AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH
Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in
Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesLongitude CapitalNovo HoldingsOrbiMed+6 more
Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Michael Tolentino(Executive Officer, Director)inMohamed A. Genead(Chairman & CEO)inDavid Callanan(Executive Officer)inDerek Kunimoto(Executive Officer)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in
Co-investorsLongitude CapitalCatalio Capital Management, LPOrbiMedAvoro Capital AdvisorsDigitalis VenturesOmega Funds
Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.
BiotechDeep TechHealthtechMedical DevicesLeiden, NL
Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)
Co-investorsBioGeneration VenturesBioMedPartnersForbionPictet GroupAsahi Kasei Corporate Venture CapitalSeroba Life Sciences
Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.
BiotechHealthtech
Frédéric Marrache(Co-founder & CEO)in
Co-investorsSanofi VenturesSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsBioqube VenturesBrandon CapitalForbionBayern KapitalBioGeneration VenturesCanaan Partners+2 more
CDR-Life is a biotech company developing antibody-based therapeutics, with a focus on its proprietary platform and clinical pipeline.
AI & Machine LearningBiotechHealthtechHorgen, CH
Rouven Bingel-Erlenmeyer(Founder)inChristian Leisner(Co-founder)inDominik Escher(Co-founder)
Co-investorsRA Capital
Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.
BiotechDigital HealthHealthtechLongevity
Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin
Co-investorsFountain Healthcare PartnersKurma PartnersOrbiMedV-Bio VenturesOmnes CapitalInvivo Capital Partners+1 more
NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.
BiotechDeep TechHealthtechMedical DevicesAarhus, DK
Co-investorsNovo HoldingsInkefRoche Venture FundLundbeckfonden Ventures
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)inGary D. Glick(Founder)Gary D. Glick, Ph.D.(Founder, President & CEO)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)
Board seatKsenija Pavletic· per SEC Form D
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+9 more
Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.
BiotechDigital HealthMedical Devices
Co-investorsVida VenturesYsios CapitalHealthCap
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical DevicesCopenhagen, DK
Michael Pehl, MSc(Chief Executive Officer)
Co-investorsVida VenturesHealthCapNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+5 more
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundKurma PartnersNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
Co-investorsAdBio partnersAsabys PartnersNovo HoldingsPMVV-Bio VenturesNewton Biocapital
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsOmega FundsFrazier Life SciencesNorwest Venture Partners
EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.
BiotechHealthtechHolborn, London
David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)
Co-investorsSamsara BioCapitalOmega FundsSV Health Investors
Biotech company developing antibodies to treat autoimmune and inflammatory diseases.
Co-investorsAlpha Wave GlobalArkin CapitalArkin Digital HealthMonograph Capital PartnersViking GlobalARCH Venture Partners+1 more
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Co-investorsEcoR1 CapitalVida VenturesTPG
Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.
BiotechHealthtechMedical Devices
Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in
Co-investorsBioMedPartnersRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+3 more
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalAsahi Kasei Corporate Venture CapitalDementia Discovery FundF-Prime CapitalLongwood FundSR One Capital Management+4 more
Quell Therapeutics is a clinical-stage biopharmaceutical company developing targeted Treg cell therapies with advanced manufacturing capabilities.
BiotechDeep TechHealthtechMedical Devices
Co-investorsAlbionVCSV Health InvestorsUCL Technology Fund
ReproNovo develops therapeutic solutions for male and female fertility and women's health conditions like adenomyosis, targeting unmet medical needs in reproductive medicine.
BiotechFemTechHealthtechMedical DevicesLausanne, CH
Co-investorsM VenturesYsios Capital
SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system.
BiotechDeep TechDigital HealthMedical Devices
Co-investorsAdBio partnersYsios Capital
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.
BiotechHealthtechMedical DevicesMalvern, US
Ronald Crystal(Founder and Advisor (Board Observer))Todd Rosengart(Founder; Board Observer)John Tucker(President and CEO)Albert Gianchetti(Executive Officer, Director)
BoardGlenn Batchelder(Director)inJames Cohen(Director)
Co-investorsFountain Healthcare PartnersLumira VenturesLongwood FundSofinnova Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Callio TherapeuticsEyeBio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.